Encopresis Medication

  • Author: Stephen Borowitz, MD; Chief Editor: Carmen Cuffari, MD   more...
 
Updated: May 11, 2012
 

Medication Summary

Because most children with encopresis have retentive encopresis as a consequence of chronic constipation with resulting overflow incontinence, therapy is initially focused on evacuating the distal colon.[20] Disimpaction can be accomplished with aggressive use of oral cathartics (eg, polyethylene glycol [PEG], sodium phosphate, magnesium citrate) or a series of enemas. In clinical trials, disimpaction by the oral route or the rectal route is reported to be equally effective.[21, 22]

After the colon is evacuated, long-term laxative therapy is generally started. Virtually any laxative can be used as long as it is used in sufficient quantity to produce 1-2 soft stools per day.

Next

Osmotic laxatives

Class Summary

These agents cause fluid retention in the colon, lowering the pH, resulting in distention, and increasing colonic peristalsis.

Polyethylene glycol powder (MiraLax, GlycoLax)

 

PEG is a long chain of ethylene glycol molecules. The resulting molecule is extremely large, is very poorly absorbed, and functions as an osmotic laxative. These powders are tasteless and odorless and completely dissolve in nearly all liquids including water. These agents can also be used as purgatives in preparation for colonoscopy. At very large dosages, PEG is occasionally difficult to take, and its usage may be associated with nausea, bloating, abdominal cramps, and vomiting.

Magnesium hydroxide (Philip's Milk of Magnesia, Haley's MO)

 

Magnesium is divalent cation maximally absorbed in distal small intestine. At low concentrations, magnesium appears to be absorbed in saturable carrier-mediated process influenced by vitamin D. At high concentrations, absorption appears to occur largely and inefficiently by diffusion. Increased serum magnesium levels may cause cholecystokinin release, which stimulates GI motility and secretion; may explain why some children have abdominal cramping. Mostly flavorless; thick, chalky texture. Most palatable when mixed with fluid (eg, milk, chocolate milk).

Lactulose (Constilac, Duphalac, Kristalose)

 

Synthetic nonabsorbable disaccharide. Available as 70% solution. Generally well tolerated and tastes sweet.

Sorbitol

 

Hyperosmotic laxative. Cathartic actions in GI tract. This alcohol of glucose is largely nonabsorbable. Available as 70% solution. Generally well tolerated and tastes sweet.

Magnesium citrate (Evac-Q-mag)

 

Magnesium is divalent cation maximally absorbed in the distal small intestine. At low concentrations, magnesium appears to be absorbed in saturable carrier-mediated process influenced by vitamin D. At high concentrations, magnesium absorption appears to occur largely and inefficiently by diffusion. Increased serum magnesium levels may cause cholecystokinin release, which stimulates GI motility and secretion; may explain why some children have abdominal cramping. May be chilled to improve palatability.

Sodium acid phosphate (Fleet Phospho-Soda)

 

Phosphate is a divalent anion largely absorbed in the proximal small intestine. When administered as an enema, only small amounts are absorbed so the phosphate functions as an osmotic agent. Each 15 mL contains 7.2 g monobasic sodium phosphate monohydrate and 2.7 g dibasic sodium phosphate heptahydrate.

Previous
Next

Lubricants and emollients

Class Summary

These agents retard colonic absorption of fecal water and thus soften stool.

Mineral oil

 

Nonabsorbable fat that softens stool and decreases water absorption, partly by its metabolism in colon to hydroxy fatty acids. Largely tasteless and has oily consistency. Most palatable if cold or mixed into a fluid (eg, orange juice). In many children given high doses, causes seepage of orange oil into underwear, which can produce perianal pruritus.

Previous
Next

Stimulant laxatives

Class Summary

These agents directly act on the intestinal mucosa or nerve plexus. They alter water and electrolyte secretion.

Sennosides (Senokot, Ex-Lax, Fletcher's Castoria, Aloe Vera)

 

Plant alkaloids that stimulate colonic salt and water secretion and promote colonic motility. Often produce abdominal cramping at high doses. Long-term use in animals not been associated with any evidence of cathartic colon, tachyphylaxis, or secondary hyperaldosteronism.

Bisacodyl (Dulcolax)

 

Colorless and odorless compound absorbed poorly. Administered PO or PR. Increases colonic peristalsis and stimulates salt and water secretion.

Previous
Next

Enemas

Class Summary

Several days of enemas are often used to evacuate or disimpact the colon before the start of a regular laxative regimen. Various enema preparations can be used to evacuate the distal colon. Most enema preparations contain osmotically active agents that are not substantially absorbed in the colon. Common examples include phosphate (eg, Fleet pediatric, adult enemas), saline, or milk and molasses. To the author's knowledge, no studies have been performed to compare the effectiveness of various enema preparations. In all likelihood, the effectiveness of any particular preparation depends more on the volume of the enema than on the composition of the enema solution.

Sodium acid phosphate (Fleet Enema)

 

Phosphate is divalent anion absorbed largely in proximal small intestine. Functions as osmotic agent and only small amounts are absorbed when administered as enema.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Stephen Borowitz, MD  Professor of Pediatrics and Public Health Sciences, Department of Pediatrics, Division of Gastroenterology and Nutrition, University of Virginia School of Medicine

Stephen Borowitz, MD is a member of the following medical societies: American Academy of Pediatrics, American Gastroenterological Association, American Pediatric Society, North American Society for Pediatric Gastroenterology and Nutrition, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Jorge H Vargas, MD  Professor of Pediatrics and Clinical Professor of Pediatric Gastroenterology, University of California, Los Angeles, David Geffen School of Medicine; Consulting Physician, Department of Pediatrics, University of California at Los Angeles Health System

Jorge H Vargas, MD is a member of the following medical societies: American Liver Foundation, American Society for Gastrointestinal Endoscopy, American Society for Parenteral and Enteral Nutrition, Latin American Society of Pediatric Gastroenterology, Hepatology & Nutrition, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Steven M Schwarz, MD, FAAP, FACN, AGAF  Professor of Pediatrics, Children's Hospital at Downstate, State University of New York Downstate Medical Center

Steven M Schwarz, MD, FAAP, FACN, AGAF is a member of the following medical societies: American Academy of Pediatrics, American College of Nutrition, American College of Physician Executives, American Gastroenterological Association, American Pediatric Society, Gastroenterology Research Group, New York Academy of Medicine, North American Society for Pediatric Gastroenterology and Nutrition, and Society for Pediatric Research

Disclosure: Curemark, LLC Consulting fee Board membership; Centocor, Inc. Grant/research funds Independent contractor; Johnson & Johnson, Inc. Grant/research funds Independent contractor

Chief Editor

Carmen Cuffari, MD  Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

References
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. APA; 2000.

  2. Di Lorenzo C, Benninga MA. Pathophysiology of pediatric fecal incontinence. Gastroenterology. Jan 2004;126(1 Suppl 1):S33-40. [Medline].

  3. Partin JC, Hamill SK, Fischel JE, Partin JS. Painful defecation and fecal soiling in children. Pediatrics. Jun 1992;89(6 Pt 1):1007-9. [Medline].

  4. Borowitz SM, Cox DJ, Sutphen JL. Differences in toileting habits between children with chronic encopresis, asymptomatic siblings, and asymptomatic nonsiblings. J Dev Behav Pediatr. Jun 1999;20(3):145-9. [Medline].

  5. Joinson C, Heron J, Butler U, et al. Psychological differences between children with and without soiling problems. Pediatrics. May 2006;117(5):1575-84. [Medline].

  6. Loening-Baucke V. Prevalence rates for constipation and faecal and urinary incontinence. Arch Dis Child. Jun 2007;92(6):486-9. [Medline].

  7. van der Wal MF, Benninga MA, Hirasing RA. The prevalence of encopresis in a multicultural population. J Pediatr Gastroenterol Nutr. Mar 2005;40(3):345-8. [Medline].

  8. Joinson C, Heron J, Butler R, et al. A United Kingdom population-based study of intellectual capacities in children with and without soiling, daytime wetting, and bed-wetting. Pediatrics. Aug 2007;120(2):e308-16. [Medline].

  9. Cox DJ, Morris JB Jr, Borowitz SM, Sutphen JL. Psychological differences between children with and without chronic encopresis. J Pediatr Psychol. Oct-Nov 2002;27(7):585-91. [Medline].

  10. Mellon MW, Whiteside SP, Friedrich WN. The relevance of fecal soiling as an indicator of child sexual abuse: a preliminary analysis. J Dev Behav Pediatr. Feb 2006;27(1):25-32. [Medline].

  11. Johnston BD, Wright JA. Attentional dysfunction in children with encopresis. J Dev Behav Pediatr. Dec 1993;14(6):381-5. [Medline].

  12. Borowitz SM, Sutphen J, Ling W, Cox DJ. Lack of correlation of anorectal manometry with symptoms of chronic childhood constipation and encopresis. Dis Colon Rectum. Apr 1996;39(4):400-5. [Medline].

  13. McGrath ML, Mellon MW, Murphy L. Empirically supported treatments in pediatric psychology: constipation and encopresis. J Pediatr Psychol. Jun 2000;25(4):225-54; discussion 255-6. [Medline].

  14. Nolan T, Debelle G, Oberklaid F, Coffey C. Randomised trial of laxatives in treatment of childhood encopresis. Lancet. Aug 31 1991;338(8766):523-7. [Medline].

  15. Borowitz SM, Cox DJ, Sutphen JL, Kovatchev B. Treatment of childhood encopresis: a randomized trial comparing three treatment protocols. J Pediatr Gastroenterol Nutr. Apr 2002;34(4):378-84. [Medline].

  16. Thapar A, Davies G, Jones T, Rivett M. Treatment of childhood encopresis--a review. Child Care Health Dev. Nov-Dec 1992;18(6):343-53. [Medline].

  17. [Best Evidence] [Guideline] Brazzelli M, Griffiths PV, Cody JD, Tappin D. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. Cochrane Database Syst Rev. Dec 7 20011;CD002240. [Medline].

  18. Ritterband LM, Cox DJ, Walker LS, et al. An Internet intervention as adjunctive therapy for pediatric encopresis. J Consult Clin Psychol. Oct 2003;71(5):910-7. [Medline].

  19. Ritterband LM, Ardalan K, Thorndike FP, et al. Real world use of an Internet intervention for pediatric encopresis. J Med Internet Res. 2008;10(2):e16. [Medline]. [Full Text].

  20. Dobson P, Rogers J. Assessing and treating faecal incontinence in children. Nurs Stand. Sep 16-22 2009;24(2):49-56; quiz 58, 60. [Medline].

  21. Bekkali NL, van den Berg MM, Dijkgraaf MG, van Wijk MP, Bongers ME, Liem O. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG. Pediatrics. Dec 2009;124(6):e1108-15. [Medline].

  22. Miller MK, Dowd MD, Friesen CA, Walsh-Kelly CM. A randomized trial of enema versus polyethylene glycol 3350 for fecal disimpaction in children presenting to an emergency department. Pediatr Emerg Care. Feb 2012;28(2):115-9. [Medline].

  23. Cox DJ, Sutphen J, Borowitz S, et al. Contribution of behavior therapy and biofeedback to laxative therapy in the treatment of pediatric encopresis. Ann Behav Med. Spring 1998;20(2):70-6. [Medline].

  24. Brooks RC, Copen RM, Cox DJ, et al. Review of the treatment literature for encopresis, functional constipation, and stool-toileting refusal. Ann Behav Med. 2000;22(3):260-7. [Medline].

  25. Brazzelli M, Griffiths P. Behavioural and cognitive interventions with or without other treatments for defaecation disorders in children. Cochrane Database Syst Rev. 2001;(4):CD002240. [Medline].

  26. Young MH, Brennen LC, Baker RD, Baker SS. Functional encopresis: symptom reduction and behavioral improvement. J Dev Behav Pediatr. Aug 1995;16(4):226-32. [Medline].

  27. Reid H, Bahar RJ. Treatment of encopresis and chronic constipation in young children: clinical results from interactive parent-child guidance. Clin Pediatr (Phila). Mar 2006;45(2):157-64. [Medline].

  28. Rockney RM, McQuade WH, Days AL, et al. Encopresis treatment outcome: long-term follow-up of 45 cases. J Dev Behav Pediatr. Dec 1996;17(6):380-5. [Medline].

Previous
Next
 
Overflow incontinence.
Overflow incontinence.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.